FRM
UTHR icon

Fox Run Management’s United Therapeutics UTHR Stock Holding History

Fox Run Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,627
Closed -$1.28M – 1254
2025
Q4 		$1.28M Buy
+2,627
New +$1.22M 0.2% 123
2025
Q2 		– Sell
-6,129
Closed -$1.89M – 1258
2025
Q1 		$1.89M Buy
6,129
+4,913
+404% +$1.68M 0.29% 35
2024
Q4 		$429K Buy
+1,216
New +$447K 0.08% 487
2024
Q2 		– Sell
-5,185
Closed -$1.19M – 1102
2024
Q1 		$1.19M Sell
5,185
-1,704
-25% -$385K 0.26% 86
2023
Q4 		$1.51M Buy
6,889
+5,668
+464% +$1.31M 0.39% 17
2023
Q3 		$276K Buy
+1,221
New +$281K 0.08% 475
2022
Q4 		– Sell
-2,377
Closed -$498K – 899
2022
Q3 		$498K Buy
+2,377
New +$531K 0.19% 180
2021
Q4 		– Sell
-2,527
Closed -$466K – 710
2021
Q3 		$466K Buy
+2,527
New +$498K 0.29% 99
2020
Q4 		– Sell
-1,994
Closed -$201K – 295
2020
Q3 		$201K Buy
+1,994
New +$219K 0.5% 126
2020
Q1 		– Sell
-3,360
Closed -$296K – 372
2019
Q4 		$296K Sell
3,360
-32
-0.9% -$2.82K 0.24% 205
2019
Q3 		$271K Sell
3,392
-1,893
-36% -$152K 0.25% 192
2019
Q2 		$413K Buy
+5,285
New +$494K 0.27% 125
2018
Q4 		– Sell
-4,406
Closed -$563K – 745
2018
Q3 		$563K Buy
4,406
+2,027
+85% +$251K 0.25% 139
2018
Q2 		$269K Buy
+2,379
New +$261K 0.09% 481
2017
Q3 		– Sell
-4,200
Closed -$545K – 880
2017
Q2 		$545K Buy
+4,200
New +$524K 0.19% 196
2016
Q4 		– Sell
-4,200
Closed -$496K – 684
2016
Q3 		$496K Buy
+4,200
New +$505K 0.29% 105
2016
Q2 		– Sell
-4,200
Closed -$468K – 677
2016
Q1 		$468K Buy
+4,200
New +$531K 0.31% 95

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fox Run Management's UTHR Position: Q1 2026 in Review

Fox Run Management sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 2,627 shares — an estimated $1.28M sold.

Fox Run Management first reported a position in UTHR in Q1 2016 and held it in 17 quarters. The position peaked at $1.89M in Q1 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Fox Run Management reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 2,627 United Therapeutics shares in Q1 2026, an estimated $1.28M.
  • Fox Run Management first reported a position in United Therapeutics in Q1 2016 and held it in 17 quarters.
  • Fox Run Management's United Therapeutics position peaked at $1.89M in Q1 2025.
  • 854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.